Steven Hess
Cardiovascular Disease · Philadelphia, PANPI 1245233204
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 115 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 16.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,175 and has fallen 92.9% since, to $83 in 2023. That places this record below the midpoint for cardiovascular disease clinicians in PA, where the typical reported total is $1,447.
Across 115 payments — averaging $15.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$278
- Johnson & Johnson$241
- Pfizer$198
- Boston Scientific$156
- Sanofi-aventis U.S. LLC$133
- Amarin Pharma, Inc.$100
- plus $620 from 15 others
What the payments were for
- Food & beverage$1,719100%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 18 | $278 |
| Johnson & Johnson | 17 | $241 |
| Pfizer | 21 | $198 |
| Boston Scientific | 8 | $156 |
| Sanofi-aventis U.S. LLC | 9 | $133 |
| Amarin Pharma, Inc. | 7 | $100 |
| Boehringer Ingelheim | 6 | $92 |
| Astellas Pharma US Inc | 6 | $82 |
| AstraZeneca | 6 | $77 |
| Daiichi Sankyo Inc. | 2 | $48 |
| Regeneron Healthcare Solutions, Inc. | 3 | $46 |
| Novartis | 1 | $43 |
| Almirall LLC | 1 | $42 |
| Sun Pharmaceutical Industries Inc. | 1 | $39 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $28 |
| Abbott | 2 | $27 |
| Edwards Lifesciences | 1 | $24 |
| Genentech USA, Inc. | 1 | $23 |
| VYNE Pharmaceuticals Inc. | 1 | $23 |
| Atricure, Inc. | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
How this compares
$1,726 in reported general payments places this provider in the 50th percentile of 1,250 cardiovascular disease providers in Pennsylvania.
Other cardiovascular disease in Philadelphia
- Paul ForfiaPhiladelphia$1.2M
- Quang BuiPhiladelphia$933K
- Dean KaralisPhiladelphia$385K
- Manavendra BakhshiPhiladelphia$250K
- Philip HainesPhiladelphia$170K
- Julio ChirinosPhiladelphia$145K
- Michael MillerPhiladelphia$133K
- Nehal MehtaPhiladelphia$129K
- Garo GaribianPhiladelphia$115K
- Norman FeinsmithPhiladelphia$94K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.